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Abstract 
Background: Manganese toxicity can occur as a complication of home parenteral nutrition (HPN). 
Patients can present with Parkinson disease-like symptoms. Preparations of trace elements in parenteral 
nutrition generally provide amounts in excess of requirements. Our previous review observed 60% of 
adult HPN patients to have high whole-blood manganese levels. Multi-trace element solutions were 
subsequently removed from all HPN formulations in January 2015. The aim of this service evaluation 
was to determine whole-blood concentrations of manganese in adult patients receiving HPN at the 
same institution to establish whether levels are now maintained within the normal reference range. 
Methods: A retrospective review of whole-blood manganese levels in all patients receiving HPN 
between January 2018 and January 2019 from one hospital site was carried out.  
Results: 100 patients were included in the review (59 female and 41 male). Normal whole-blood 
manganese levels (73-219 nmol/L) were observed in 70% of patients and elevated levels (>219 nmol/L) 
in 30% of patients. In the patients with elevated levels, 57% hadn’t received manganese 
supplementation for at least one year prior to manganese being measured. Markers of cholestasis were 
similar between the two groups. 
Conclusions: Incidence of elevated whole-blood manganese concentrations in patients receiving home 
parenteral nutrition decreased from 60% to 30% upon discontinued use of a multi-trace element 
solution. Elevated levels remain a concern despite patients being prescribed ‘manganese-free’ 
parenteral nutrition. Patients receive this trace element in amounts adequate to meet requirements 
through contamination and dietary intake alone, suggesting additional parenteral supplementation of 
manganese is not required. 
Introduction 
Manganese (Mn), an essential trace element (TE), is a cofactor for metalloenzymes, involved in 
processes such as immune and reproductive function, detoxification of damaging free radicals and 
neuronal health.1 Less than 5% of dietary Mn is absorbed and of that 90% is excreted through the biliary 
tract.2 Elevated Mn concentrations have been documented in patients with cholestasis but also in those 
with normal liver function.3-5 Detected by T1-weighted magnetic resonance imaging (MRI), excess Mn 
has been shown to accumulate in the brain at the level of the basal ganglia and can lead to 
neurotoxicity, a condition referred to as manganism.6 This might present as a Parkinsonian-like illness. 
Mn is typically provided as part of a commercially available pre-mixed multi-trace element (MTE) 
solution in all patients receiving parenteral nutrition (PN). Additional Mn exposure is known to occur as 
a result of contamination via PN additives,7 likely at a level to meet requirements.8 Recommended 
standard doses of Mn in PN for adults have been decreasing (Table 1).9-13  
In 2014, a previous review at our institution observed 60% of HPN patients to have high whole-blood Mn 
levels.14 Practice was changed and multi-trace element solutions were subsequently removed from all 
HPN formulations in January 2015. Rather, the trace elements zinc, selenium, iron and copper were 
added individually. Prescribing restrictions within the hospital meant inpatient PN still contained a MTE 
solution with 275 µg of Mn in each PN formulation. The aim of this service evaluation was to determine 
whole-blood concentrations of Mn in adult patients treated with HPN at the same institution to 
establish whether levels are now maintained within the normal reference range (73-219 nmol/L).  
Methods 
Population demographics: A retrospective review of whole-blood Mn levels in 100 adult patients 
receiving home parenteral nutrition (HPN) between January 2018 and January 2019 from one centre 
was carried out. Patient demographics and parenteral nutrition (PN) data include age, gender, length of 
time on PN, number of PN infusions per week, Mn level, and Mn exposure. Exposure to Mn describes 
the number of days exposed to the multi-trace element (MTE) preparation, Additrace (Fresenius Kabi, 
UK), in the 12 months prior to having Mn measured. Additrace contains 275 µg of Mn per 10ml 
ampoule.  
Sampling: All samples were analysed in the Department of Blood Sciences at our hospital. Blood for Mn 
analysis was taken into navy blue top (trace element-free) tubes (BD Vacutainer). Blood for routine tests 
was taken into gold top serum separator tubes (BD Vacutainer). Mn in whole-blood was analysed by 
inductively-coupled plasma-mass spectrometry in standard mode.  
Statistics: Patients were grouped into those with normal whole-blood Mn levels (73-219 nmol/L), or 
elevated levels (>219 nmol/L). Data were entered into Microsoft Excel 2016, MSO (16.0.4738.1000) 32-
bit and statistical analysis performed using two sample t-tests assuming unequal variances. The two Mn 
groups were compared for length of time on HPN, number of HPN infusions per week, exposure to 
Additrace, and liver function tests. Statistical significance was defined by a P-value of <0.05.  
Analysis was based on retrospective anonymised information taken from patient records with full regard 
to individual confidentiality.  The project was registered on the Clinical Effectiveness Register as a 
service review, project number 8400.  
Results 
100 patients were included in the analysis. The patients ranged in age from 19 to 73 years (median 55.8 
years). Of the included patients, 51% were from our previous study in 2014. Both cohorts of patients 
were similar in terms of indications for parenteral nutrition (PN) and PN requirements. In this cohort, 
normal whole-blood Mn levels (73-219 nmol/L) were observed in 70 (70%) patients and elevated levels 
(>219 nmol/L) were observed in 30 (30%) patients. This compares to 40% and 60% of patients in 2014, 
respectively (Figure 1). Within the elevated group, 3 (10%) patients had Mn levels that were considered 
clinically very high (>400 nmol/ L). Higher Mn levels were associated with less time on HPN, indicative of 
more inpatient days in the previous 12 months. No patients demonstrated a Mn level below the 
reference interval (<73 nmol/L). Full data, expressed as medians and range, and statistical P-values are 
shown in Table 2.  
In the normal Mn group (73-219 nmol/L), 8/70 (11%) patients had received a MTE solution in the year 
prior to having Mn measured, median, 21 days, compared to 13/30 (43%) in the elevated Mn group 
(>219 nmol/L), median 40 days, (Figure 2). Conversely, there were 17/30 (57%) participants in the 
elevated Mn group that had not been exposed to Mn in the previous year. As part of the evaluation, Mn 
was measured in a subset of unused ‘Mn free’ home parenteral nutrition bags (n=6) to determine the 
concentration of Mn through contamination. Levels were found to be 80 nmol/L.  
There were no statistically significant differences between the two Mn groups for the number of 
infusions of PN per week (p=0.18), bilirubin (p=0.14) or alkaline phosphatase (p=0.38).  
Discussion 
This is the largest review of whole-blood Mn levels in patients receiving home parenteral nutrition (HPN) 
to date. It could be argued that our current practice of withholding multi-trace element (MTE) solutions 
risks deficiency of chromium, molybdenum, iodine and fluoride as individual preparations of these trace 
elements (TE) are not widely available in the UK. However, ASPEN11 and ESPEN13 do not provide 
recommendations for the routine addition of molybdenum or flouride to PN because of the widespread 
contamination of these TE. Similarly, iodine and chromium are both present as contaminants. ESPEN do 
recommend the routine addition of these TE, however, we encourage all of our patients to maintain 
some oral intake, particularly dairy and milk products which are rich in iodine and chromium, 
respectively. There have been no concerns of deficiency of these TE in our cohort of patients, although 
levels have not specifically been measured due to lack of reliable tests available.  
As expected, higher Mn levels were observed in patients who had been exposed to a MTE solution as an 
inpatient in the 12 months prior to having Mn measured. Patients receive this MTE solution during 
unplanned hospital admissions and whilst being established on parenteral nutrition (PN). Only upon 
discharge would they receive ‘Mn-free’ PN provided by the homecare company. This explains higher Mn 
levels in those patients who have been receiving HPN the least length of time.  
There were 17 patients (57%) in the elevated Mn group who had not received a MTE solution in the 12 
months prior to having Mn measured. There are three likely explanations for the elevated levels 
observed. It is well known that the ingredients of PN are contaminated with Mn. The subset of ‘Mn free’ 
HPN bags (n=6) that were subjected to lab analysis contained Mn levels of 80 nmol/L; levels consistent 
with previous reports.15-16 
A second explanation could be in relation to altered liver function. Excess Mn is normally excreted via 
the biliary tract and previous studies have shown high levels to be associated with cholestasis.17-18 In our 
patients however, there were no statistically significant differences between the two groups for bilirubin 
or alkaline phosphatase levels. Another explanation is in relation to dietary intake. All of our patients are 
encouraged to maintain some dietary and fluid intake. Although oral intake data were not collected for 
the purpose of this review; it is worth highlighting that tea is commonly consumed in our patient group.  
Moreover, a standard mug of tea (250mL) contains on average 0.45-1.3 mg (450-1300 µg) of Mn.19 
To prevent potential deficiencies of other TE, and to minimise future exposure to Mn for HPN patients, 
alternative MTE preparations containing 55µg of Mn have been sought. A key finding in this review, 
however, is that there were no patients within this cohort that were deficient in Mn (<73 nmol/L), 
despite Mn being completely withheld from PN in 79/100 (79%) patients over the previous year. It is 
therefore possible that we may continue to see elevated Mn levels at supplementation levels of 55 µg 
per day. Whole-blood Mn levels will continue to be measured in all HPN patients at six monthly 
intervals. Data will be reviewed in 12 months time to establish whether our change in practice has been 
effective in reducing the currently observed elevated whole-blood Mn levels.  
Limitations 
A limitation of the present evaluation is in defining those patients exposed to Mn via a multi-trace 
element (MTE) solution in the previous twelve months. It is unclear how long whole-blood Mn levels 
take to normalise following exposure and is likely dependant on multiple factors. A duration of 5 to 9 
months has been reported in some studies,20-21 and therefore a 12-month period for re-assessment was 
deemed adequate.  
Conclusion 
Incidence of elevated whole-blood manganese concentrations in patients receiving home parenteral 
nutrition (HPN) decreased from 60% to 30% upon discontinued use of multi-trace element solutions. 
However, elevated levels are an ongoing concern and are being seen in patients receiving ‘Mn-free’ 
HPN. Patients are receiving this trace element in amounts adequate to meet requirements through 
contamination and dietary intake alone; suggesting additional parenteral supplementation of Mn is not 
required. Research is required to determine the relationship between high whole-blood Mn levels and 
any adverse clinical outcome. 
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Table 1: Recommended parenteral Mn supplementation in adults. AMA = American Medical Association. 
ASPEN = American Society for Parenteral and Enteral Nutrition. AuSPEN = Australasian Society for 
Parenteral and Enteral Nutrition. ESPEN = European Society for Clinical Nutrition and Metabolism.  
Source Year Mn dose (µg/day) 
AMA 1979 150-800 
ESPEN 2009 165-275 
ASPEN 2012 55 
AuSPEN 2014 55 
ESPEN 2016 60-100 
 
Table 2: Demographic and parenteral nutrition data. E-Mn = elevated manganese, F = female, GI = 
gastrointestinal, HPN = home parenteral nutrition, IBD = inflammatory bowel disease, M = male, N = 
number of patients. Data are expressed as medians and range. N-Mn = normal manganese, PN = 
parenteral nutrition, SB = small bowel 
Demographics and 
Parenteral Nutrition Data 
Normal -Mn (73-219 
nmol/L) 
Elevated -Mn 
(>220nmol/L) 
Statistical 
significance 
N = 100 (59F, 41M) N = 70 (39F, 31M) N = 30 (20F, 10M)  
Median age (range; 
years) 
57.1 (19-83) 52.7 (20-71)  
Indications for HPN (n): 
IBD 
SB ischaemia 
GI dysmotility 
Other 
 
18 
22 
12 
18 
 
13 
3 
1 
13 
 
Median Mn level 
(range; nmol/L) 
158.8 (76-219) 271.7 (222.6-
482.8) 
 
N (%) patients exposed 
to inpatient Additrace 
in the previous 12 
months 
 
8 (11) 
 
13 (43) p <0.001 
Median length of time 
on HPN (range; 
months) 
47.5 (9-254) 30 (6-100) P <0.001 
 
 
 
Figure 1. Comparison of blood Mn levels from 2014 to 2018 
Abbreviations: n = number of patients 
 
Figure 2. Effect of inpatient exposure to Additrace in the previous 12 months on Mn levels  
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